%PDF-1.4
%
64 0 obj
<>
endobj
61 0 obj
<>
endobj
183 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-07-09T09:23:40Z
2024-03-29T23:08:36-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T23:08:36-07:00
application/pdf
Heather
2003-626.aug
uuid:88edc3c4-1dd2-11b2-0a00-af0827edca00
uuid:88edc3c6-1dd2-11b2-0a00-380000000000
endstream
endobj
50 0 obj
<>
endobj
51 0 obj
<>
endobj
65 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
21 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
212 0 obj
[217 0 R]
endobj
213 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:8)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1574)Tj
/T1_2 1 Tf
-0.00011 Tc 0.02499 Tw 0.375 84.8494 Td
[(13.)-875 (Roychowdhury B, Bintley-Bagot S, Bulgen DY)129 (, )18 (Thompson RN,)]TJ
2.175 -1.25 Td
[(T)35 (unn EJ, Moors RJ. Is methotrexate ef)18 (fective in ankylosing)]TJ
0 -1.25 TD
(spondylitis? Rheumatology 2002;41:1330-2.)Tj
-2.175 -1.25 Td
[(14.)-875 (V)111 (an der Linden S, )18 (V)111 (alkenbur)18 (g HA, Cats )55 (A. Evaluation of diagnostic)]TJ
2.175 -1.25 Td
(criteria for ankylosing spondylitis: a proposal for modification of)Tj
T*
[(the New )37 (Y)100 (ork criteria. )55 (Arthritis Rheum 1984;27:361-8.)]TJ
-2.175 -1.25 Td
[(15.)-875 (Garret S, Jenkinson )18 (T)74 (, Kennedy LG, )18 (Whitelock H, Gaisford P)111 (,)]TJ
2.175 -1.25 Td
[(Calin )55 (A. )55 (A)-220 (new approach to defining disease status in ankylosing)]TJ
T*
[(spondylitis: the Bath )55 (Ankylosing Spondylitis Disease )55 (Activity)]TJ
T*
(Index. J Rheumatol 1994;21:2286-91.)Tj
-2.175 -1.25 Td
[(16.)-875 (Felson DT)74 (, )55 (Anderson JJ, Boers M, et al. )55 (American College of)]TJ
2.175 -1.25 Td
[(Rheumatology)65 (. Preliminary definition of improvement in )]TJ
T*
[(rheumatoid arthritis. )55 (Arthritis Rheum 1995;38:727-35. )]TJ
-2.175 -1.25 Td
[(17.)-875 (V)111 (an der Heijde D, Calin )55 (A, Dougados M, Khan MA, )18 (V)111 (an der)]TJ
2.175 -1.25 Td
(Linden S, Bellamy N. Selection of instruments in the core set for)Tj
T*
[(DC-AR)60 (T)74 (, SMARD, physical therapy)65 (, and clinical record keeping in)]TJ
T*
[(ankylosing spondylitis. Progress report of the )55 (ASAS )18 (W)80 (orking)]TJ
T*
(Group. J Rheumatol 1999;26:951-4.)Tj
-2.175 -1.25 Td
[(18.)-875 (Calin )55 (A, Garrett S, )18 (Whitelock H, et al. )55 (A)-220 (new approach to defining)]TJ
2.175 -1.25 Td
(functional ability in ankylosing spondylitis: the development of the)Tj
T*
[(Bath )55 (Ankylosing Spondylitis Functional Index. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1994;21:2281-5.)Tj
-0.00011 Tc 0.02499 Tw 30.825 26.25 Td
[(19.)-875 (Daltroy LH, Larson MG, Roberts )18 (WN, Liang MA. Modification of)]TJ
2.175 -1.25 Td
[(the Health )55 (Assessment Questionnaire for the spondyloarthropathies.)]TJ
T*
(J Rheumatol 1990;17:946-50.)Tj
-2.175 -1.25 Td
[(20.)-875 (Altman DG, Machin D, Bryant )18 (TN, Gardner MJ. Statistics with)]TJ
0 Tc 2.175 -1.25 Td
(confidence. 2nd ed. London: BMJ Books; 2000.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(21.)-875 (Zink )55 (A, Braun J, Listing J, )18 (W)80 (ollenhaupt J. Disability and handicap)]TJ
2.175 -1.25 Td
(in rheumatoid arthritis and ankylosing spondylitis \321 Results from)Tj
T*
(the German rheumatological database. J Rheumatol )Tj
0 Tc 0 Tw T*
(2000;27:613-22.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(22.)-875 (Braun J, Brandt J, Listing J, et al. Long-term ef)18 (ficacy and safety of)]TJ
2.175 -1.25 Td
[(infliximab in the treatment of ankylosing spondylitis: )55 (An open,)]TJ
T*
(observational, extension study of a three-month, randomized,)Tj
T*
[(placebo-controlled trial. )55 (Arthritis Rheum 2003;48:2224-33.)]TJ
-2.175 -1.25 Td
[(23.)-875 (V)111 (an der Heijde D, Braun J, McGonagle D, Siegel J. )18 (T)35 (reatment trials)]TJ
2.175 -1.25 Td
[(in ankylosing spondylitis: current and future considerations. )55 (Ann)]TJ
T*
(Rheum Dis 2002;61:24-32.)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
109.22 59.08 396.48 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
119.868 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
44 0 obj
<>stream
8;Z\t$PL<1#Xl6'"hBXo@9JciX0%E-5+T'E:fn![]+@2\RJHZfr%5q3gp3(IQRR]P
@FB#bk$`OXl0P@]`FQ-:jfE/#@^iA.!eFYb!HX0]pEBV3\/9qGl3t!2%_L$FWq=3oJP]s@NdIt^UWt@
endstream
endobj
48 0 obj
[/Indexed/DeviceRGB 255 47 0 R]
endobj
47 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
118 0 obj
<>
endobj
67 0 obj
<>
endobj
74 0 obj
<>
endobj
143 0 obj
<>
endobj
189 0 obj
<>
endobj
73 0 obj
<>
endobj
94 0 obj
<>stream
HtT TWFF-j讑@\XT4Mŕhenh 4.FAdodGlt8" qMΈOdf
2d,OwLM0+֯X5*N[YTO?f$c3v&ؘ"\22B~"?rr~[e#pmO5ڔ=p'm%]NFhT]*NGUke*b!MXҩQ:ZI'&(#TqʄZ$hUjZXIX.)LLR9waf&Ka0
%c~Vav
cG-R|D`B|bI's4
DzrøMRy7 v==C;c悙13syp0Vkak6{VK3KKhH![g.\M4nkkO6l)T2KI.h{V۽RԑBFFH0ԉ9G0IW4%,VtVVfWiLx.hj:*2:HWUU\Zr.3w<9>~asG:2)$%'J:qJݖsF=?cgV!ƌ̒Ƭjt%%]64ldȞ,H
؛N˖:Jr0PdXLmx;eFcxBZ5hR#'b)aD0{0b$/^^n>PpzC2oWԶ~,y(G2/`Ӛt~3&p,ЇD_ٲPrюɷ]P_3!6z!hl}$!
ׁڰ5a,rTRg+rd'sk>6^q;+{`92ye v~ׅIIp
x(dD6%>?Q:.AK'3x֛2}@=5nOI;Ix<(eyI1mv<+6V)=JI_`0a?R~0Ǣ u70Ti
mZ]RWP6>>9aIP0K&t"LMl(X ^r"'s3\de?,҉.6;_>HAoO]'|oQq;_9@
x-9b('ԕS!Wb]RwZG/E(\«2<$*
Z+8.gյcgNB-S$+99VzpObgL1_:/qE-3gT11U[VV^l.ݨ"SvZt0,QRez'cczIJ&&[v^ffr݄,i''L_JF'Ae&2ڗ3eN<Tݐ Ϡo $FOtL&7OՂVƼ%ZF,Q
jNR]~?Epٶ1|6 (t4o9虢"WvpAo|nᓳ7wp/C@f#`uwb1U=U@nʃB =
: D̕g8
`z]hKc4 쏡&!.+6V2PgCvſbU&̌wtwX-"d74]x~zpBa_"-`fY+(GKiAkaLV%4xd y XÀj4|%#rTd2#gYgoމn:V7p{M%ft:[bNՕ,AFDDC3SĈ:65洳 tuwX3;f@s6a;)7Wu0J:II4śmϔ{*Moّ;9l?9''[UR/1ݨ$<9$:>&
?ܶ]ܯVnS#{?MR룷:,k뱔: Zd27e';45,91Id',ZK~KgtHLJzƳm<`t-ِ[U?)jVw!D*ws*oTW688DrW):],A"].7CM8)M&CfGKhN-%ПjO9%